COVID-19-Associated Mucormycosis (CAM): An Updated Evidence
Mapping

J 2021

COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping

HUSSAIN, Mohammad Salman, Harveen BAXI, Abanoub RIAD, Jitka KLUGAROVÁ, Andrea POKORNÁ et. al.

Basic information

Original name

COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping

Authors

HUSSAIN, Mohammad Salman (356 India, belonging to the institution), Harveen BAXI, Abanoub RIAD (818 Egypt, belonging to the institution), Jitka KLUGAROVÁ (203 Czech Republic, belonging to the institution), Andrea POKORNÁ (203 Czech Republic, belonging to the institution), Simona SLEZÁKOVÁ (203 Czech Republic, belonging to the institution), Radim LÍČENÍK (203 Czech Republic, belonging to the institution), Abul Kalam NAJMI and Miloslav KLUGAR (203 Czech Republic, guarantor, belonging to the institution)

Edition

Environmental Research and Public Health, Basel, MDPI, 2021, 1660-4601

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30304 Public and environmental health

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.614

RIV identification code

RIV/00216224:14110/21:00122477

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/ijerph181910340

UT WoS

000707124900001

Keywords in English

COVID-19; diabetes; epidemiology; evidence; mortality; mucormycosis; mycoses; public health

Abstract

V originále

Mucormycosis, a serious and rare fungal infection, has recently been reported in COVID-19 patients worldwide. This study aims to map all the emerging evidence on the COVID-19-associated mucormycosis (CAM) with a special focus on clinical presentation, treatment modalities, and patient outcomes. An extensive literature search was performed in MEDLINE (Ovid), Embase (Ovid), Cochrane COVID-19 Study Register, and WHO COVID-19 database till 9 June 2021. The primary outcome was to summarize the clinical presentation, treatment modalities, and patient outcomes of CAM. Data were summarized using descriptive statistics and presented in tabular form. This evidence mapping was based on a total of 167 CAM patients with a mean age of 51 ± 14.62 years, and 56.28% of them were male. Diabetes mellitus (73.65% (n = 123)), hypertension (22.75% (n = 38)), and renal failure (10.77% (n = 18)) were the most common co-morbidities among CAM patients. The most common symptoms observed in CAM patients were facial pain, ptosis, proptosis, visual acuity, and vision loss. Survival was higher in patients who underwent both medical and surgical management (64.96%). Overall mortality among CAM patients was found to be 38.32%. In conclusion, this study found a high incidence of CAM with a high mortality rate. Optimal glycemic control and early identification of mucormycosis should be the priority to reduce the morbidity and mortality related to CAM.

Links

EF18_053/0016952, research and development project

Name: Postdoc2MUNI

LTC20031, research and development project

Name: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministry of Education, Youth and Sports of the CR, INTER-COST

MUNI/A/1608/2020, interní kód MU

Name: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III

Investor: Masaryk University

MUNI/IGA/1543/2020, interní kód MU

Name: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Acronym: Evidence-Based Practice in Czechia)

Investor: Masaryk University

Citovat

HUSSAIN, Mohammad Salman, Harveen BAXI, Abanoub RIAD, Jitka KLUGAROVÁ, Andrea POKORNÁ, Simona SLEZÁKOVÁ, Radim LÍČENÍK, Abul Kalam NAJMI and Miloslav KLUGAR. COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. Environmental Research and Public Health. Basel: MDPI, 2021, vol. 18, No 19, p. 1-18. ISSN 1660-4601. Available from: https://dx.doi.org/10.3390/ijerph181910340.

@article{1795084,
   author = {Hussain, Mohammad Salman and Baxi, Harveen and Riad, Abanoub and Klugarová, Jitka and Pokorná, Andrea and Slezáková, Simona and Líčeník, Radim and Najmi, Abul Kalam and Klugar, Miloslav},
   article_location = {Basel},
   article_number = {19},
   doi = {http://dx.doi.org/10.3390/ijerph181910340},
   keywords = {COVID-19; diabetes; epidemiology; evidence; mortality; mucormycosis; mycoses; public health},
   language = {eng},
   issn = {1660-4601},
   journal = {Environmental Research and Public Health},
   title = {COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping},
   url = {https://www.mdpi.com/1660-4601/18/19/10340},
   volume = {18},
   year = {2021}
}

TY  - JOUR
ID  - 1795084
AU  - Hussain, Mohammad Salman - Baxi, Harveen - Riad, Abanoub - Klugarová, Jitka - Pokorná, Andrea - Slezáková, Simona - Líčeník, Radim - Najmi, Abul Kalam - Klugar, Miloslav
PY  - 2021
TI  - COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping
JF  - Environmental Research and Public Health
VL  - 18
IS  - 19
SP  - 1-18
EP  - 1-18
PB  - MDPI
SN  - 16604601
KW  - COVID-19
KW  - diabetes
KW  - epidemiology
KW  - evidence
KW  - mortality
KW  - mucormycosis
KW  - mycoses
KW  - public health
UR  - https://www.mdpi.com/1660-4601/18/19/10340
N2  - Mucormycosis, a serious and rare fungal infection, has recently been reported in COVID-19 patients worldwide. This study aims to map all the emerging evidence on the COVID-19-associated mucormycosis (CAM) with a special focus on clinical presentation, treatment modalities, and patient outcomes. An extensive literature search was performed in MEDLINE (Ovid), Embase (Ovid), Cochrane COVID-19 Study Register, and WHO COVID-19 database till 9 June 2021. The primary outcome was to summarize the clinical presentation, treatment modalities, and patient outcomes of CAM. Data were summarized using descriptive statistics and presented in tabular form. This evidence mapping was based on a total of 167 CAM patients with a mean age of 51 ± 14.62 years, and 56.28% of them were male. Diabetes mellitus (73.65% (n = 123)), hypertension (22.75% (n = 38)), and renal failure (10.77% (n = 18)) were the most common co-morbidities among CAM patients. The most common symptoms observed in CAM patients were facial pain, ptosis, proptosis, visual acuity, and vision loss. Survival was higher in patients who underwent both medical and surgical management (64.96%). Overall mortality among CAM patients was found to be 38.32%. In conclusion, this study found a high incidence of CAM with a high mortality rate. Optimal glycemic control and early identification of mucormycosis should be the priority to reduce the morbidity and mortality related to CAM.
ER  -

HUSSAIN, Mohammad Salman, Harveen BAXI, Abanoub RIAD, Jitka KLUGAROVÁ, Andrea POKORNÁ, Simona SLEZÁKOVÁ, Radim LÍČENÍK, Abul Kalam NAJMI and Miloslav KLUGAR. COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. \textit{Environmental Research and Public Health}. Basel: MDPI, 2021, vol.~18, No~19, p.~1-18. ISSN~1660-4601. Available from: https://dx.doi.org/10.3390/ijerph181910340.

Detailed Information on Publication Record